Merger looks to create bacteriophages to counter antibiotic resistance 14-May-2019 By Maggie Lynch AmpliPhi Biosciences and C3J Therapeutics merge to focus on the development of phage-based therapeutic candidates for antibiotic resistance.
Bioquell mulls sale citing investor interest in pharma and worries resistance worries as growth opportunities 19-May-2015 By Gareth Macdonald Bioquell has launched a strategic review of its contamination control technology business which could result in a sale of the company.